Coca-Cola expands into social commerce with Tweet-a-Coke
Knoxville, Tenn. — People who have a hard time finding their names on Coca-Cola’s new bottles can still share a Coke with a friend, as long as they have a Twitter account.
Coca-Cola launched the new Tweet-a-Coke campaign Tuesday, which lets a user tweet their friends a $5 e-voucher that can be redeemed for a small fountain drink at a Regal Entertainment Group theater.
"Regal Cinemas is excited to be Coca-Cola's first 'Tweet a Coke' partner," Regal Entertainment Group SVP, food service, John Curry said. "Together, Coca-Cola and Regal Cinemas have been bringing happiness to moviegoers for 12 years, and now we're teaming up to make this summer of sharing even bigger."
To give a Coke, users connect their credit card to their Twitter account, then tweet “@TweetACoke Enjoy” at the recipient.
The campaign is an expansion of the Share a Coke campaign that the company launched earlier this summer, which puts 250 of the most popular names on Coke cans and bottles. This is the first social commerce campaign for Coca-Cola, and is similar to Starbucks’ Tweet-a-Coffee campaign that it launched last year.
Rite Aid boosts selection in electronics for back-to-school
Perrigo announces first-to-file patent challenge
DUBLIN — Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.
Taro filed suit against Perrigo on July 28, claiming patent infringement. Perrigo believes it is first to file, which entitles it to a period of generic exclusivity.
"This filing highlights our continued investment in new products and dedication to bringing topicals to market. Perrigo is committed to making quality health care more affordable for consumers around the globe," said Joseph C. Papa, Perrigo's chairman, president and CEO.
Topicort is used for the treatment of plaque psoriasis in patients 18 years of age or older. The drug had annual sales of $29 million, according to Symphony Health Solutions.